Entera Bio Ltd. (NASDAQ:ENTX) Stock Has Consensus Price Target of $9.60 According to Brokerages

Entera Bio Ltd. (NASDAQ:ENTX) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $9.60.

Several research firms have issued reports on ENTX. Wall Street Zen raised shares of Entera Bio to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. UBS Group set a $9.00 target price on shares of Entera Bio in a research report on Friday, September 18th. Finally, Guggenheim began coverage on shares of Entera Bio in a research note on Thursday, September 24th. They set a “buy” rating and a $11.00 price target for the company.

Entera Bio Trading Up 1.0%

NASDAQ:ENTX opened at $3.05 on Monday. The company has a market cap of $530.46 million, a price-to-earnings ratio of -8.71 and a beta of 1.40. Entera Bio has a twelve month low of $0.91 and a twelve month high of $4.20. The stock has a fifty day simple moving average of $2.89 and a 200-day simple moving average of $2.06.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). As a group, equities research analysts predict that Entera Bio will post -0.40 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Entera Bio stock. Seven Fleet Capital Management LP boosted its position in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 51.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 205,542 shares of the company’s stock after purchasing an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned about 0.42% of Entera Bio worth $228,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company’s proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio’s pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism.